Bioethics is a shell company incorporated in Nevada with no active business operations and no revenue. Its sole purpose is to identify and acquire a business through a merger, joint venture, or asset purchase — with no defined criteria for industry, geography, or deal size. The intended model is a classic "blank check" reverse merger vehicle: insiders maintain a SEC-reporting public entity and seek a private company that wants to go public without a traditional IPO. In such a transaction, the private company's owners receive a controlling interest in the shell, contributing their business in exchange, while the shell's existing shareholders are heavily diluted. Bioethics' most notable recent activity was a September 2024 agreement to acquire SILQ Technologies via a reverse triangular merger, but that agreement expired without closing. The company funds ongoing costs — primarily legal, accounting, and office expenses — through related-party loans from its president, third-party promissory notes (several in default), convertible notes, and occasional stock sales. Bioethics pays $500/month to its president for use of his home as its office, and no officers or directors receive any other compensation.